# A Study to Learn More About the Safety and the Blood Level of BAY1747846 Given as Injection Into the Vein at Increasing Single Doses in Chinese Healthy Male Participants

> **NCT06135181** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 24 (actual)

## Conditions studied

- Contrast Enhancement in Magnetic Resonance Imaging
- Healthy Volunteers

## Interventions

- **DRUG:** Gadoquatrane (BAY1747846) 0.03 mmol Gd/kg
- **DRUG:** Gadoquatrane (BAY1747846) 0.1 mmol Gd/kg
- **DRUG:** Matching placebo

## Key facts

- **NCT ID:** NCT06135181
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-26
- **Primary completion:** 2021-02-02
- **Final completion:** 2021-04-30
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06135181

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06135181, "A Study to Learn More About the Safety and the Blood Level of BAY1747846 Given as Injection Into the Vein at Increasing Single Doses in Chinese Healthy Male Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06135181. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*